Caris Life Sciences (CAI) Short term Debt (2024 - 2026)

Caris Life Sciences' Short term Debt history runs 3 years deep, the most recent figure standing at $173000.0 for Q1 2026.

• On a quarterly basis, Short term Debt changed N/A year-over-year to $173000.0 in Q1 2026; TTM through Mar 2026 was $173000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $169000.0, down 99.72% from the prior year.
• Short term Debt grew to $173000.0 in Q1 2026 per CAI's latest filing, from $169000.0 in the prior quarter.
• Across five years, Short term Debt topped out at $60.1 million in Q4 2024 and bottomed at $95000.0 in Q2 2025.
• The 3-year median for Short term Debt is $169000.0 (2025), against an average of $12.1 million.
• Biggest YoY gain for Short term Debt was 99.72% in 2025; the steepest drop was 99.72% in 2025.
• Year by year, Short term Debt stood at $60.1 million in 2024, then tumbled by 99.72% to $169000.0 in 2025, then rose by 2.37% to $173000.0 in 2026.
• Per Business Quant, the three latest CAI Short term Debt figures stand at $173000.0 (Q1 2026), $169000.0 (Q4 2025), and $164000.0 (Q3 2025).